Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arch Biopartners Inc (ARCH.VN)

Arch Biopartners Inc (ARCH.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 83,667
  • Shares Outstanding, K 66,933
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,920 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.03
  • Most Recent Earnings $0.00 on 08/29/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (N/A)
  • Most Recent Dividend 0.200 on 09/13/00
  • Sector Medical
  • INDUSTRY GROUPING:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.980 +27.55%
on 11/19/25
1.390 -10.07%
on 12/04/25
+0.190 (+17.92%)
since 11/05/25
3-Month
0.890 +40.45%
on 10/21/25
1.680 -25.60%
on 09/11/25
-0.400 (-24.24%)
since 09/05/25
52-Week
0.890 +40.45%
on 10/21/25
2.010 -37.81%
on 01/06/25
-0.690 (-35.57%)
since 12/05/24

Most Recent Stories

More News
Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)

Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly implicated...

ARCH.VN : 1.250 (-3.85%)
ACHFF : 0.9260 (-0.41%)
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury

First patient successfully completes dosing at Toronto General Hospital St. Michael’s Hospital is expected to be the next Canadian clinical site activated Arch is looking for additional clinical sites...

ARCH.VN : 1.250 (-3.85%)
ACHFF : 0.9260 (-0.41%)
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)

TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled...

ARCH.VN : 1.250 (-3.85%)
ACHFF : 0.9260 (-0.41%)
Jobs Numbers Due in Canada Next Week

U.S. Monday Economic Lookahead S&P final U.S. manufacturing PMI (May) ISM manufacturing ...

CRWD : 512.03 (-0.21%)
PVH : 78.49 (+1.72%)
AVGO : 390.24 (+2.42%)
ARCH.VN : 1.250 (-3.85%)
CRDO : 176.04 (-2.70%)
DLTR : 122.44 (+5.67%)
GHM : 57.91 (-1.70%)
SAIC : 100.61 (-1.16%)
IOT : 45.22 (+11.08%)
FIVE : 173.20 (+2.84%)
GOT.VN : 2.510 (-2.71%)
CPB : 29.60 (+0.82%)
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

ARCH.VN : 1.250 (-3.85%)
ACHFF : 0.9260 (-0.41%)
U.S. Eases into Memorial Day Weekend

Monday U.S. Markets are Closed for Memorial Day Tuesday U.S. Economic Lookahead S&P ...

MOMO : 7.06 (+1.44%)
A : 145.49 (-1.91%)
ARCH.VN : 1.250 (-3.85%)
DAC : 98.07 (+0.34%)
HEI.A : 244.28 (-1.08%)
HPQ : 25.91 (+0.04%)
COST : 894.68 (-0.13%)
GCO : 22.73 (-6.77%)
EGT.VN : 0.140 (-3.45%)
DAC.VN : 0.035 (+600.00%)
DELL : 138.91 (-0.06%)
CRM : 260.57 (+5.30%)
Stocks in play: Arch Biopartners Inc.

Announced that it has submitted applications to the Ministry of Health (MoH) and local Ethics Committee ...

ARCH.VN : 1.250 (-3.85%)
Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage...

ARCH.VN : 1.250 (-3.85%)
ACHFF : 0.9260 (-0.41%)
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications,...

ARCH.VN : 1.250 (-3.85%)
ACHFF : 0.9260 (-0.41%)
Shares for Interest Debt Settlement

TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the...

ARCH.VN : 1.250 (-3.85%)
ACHFF : 0.9260 (-0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arch Biopartners Inc is a developer of a therapeutic pipeline designed to address acute kidney injury (AKI) and chronic kidney disease (CKD) by targeting inflammation- and toxin-related kidney damage. The group offers mechanism-based treatments, enabling patients suffering from both acute and chronic...

See More

Key Turning Points

3rd Resistance Point 1.430
2nd Resistance Point 1.390
1st Resistance Point 1.320
Last Price 1.250
1st Support Level 1.210
2nd Support Level 1.170
3rd Support Level 1.100

See More

52-Week High 2.010
Fibonacci 61.8% 1.582
Fibonacci 50% 1.450
Fibonacci 38.2% 1.318
Last Price 1.250
52-Week Low 0.890

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar